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Abstract
Background: Lithium is often used in bipolar disorder and occasionally in unipolar depression. Non-steroidal anti-inflammatory drugs (NSAIDs) and diuretics 
are frequently prescribed and their interaction with lithium is based mainly in few small studies. Objectives: Conduct a review, identify different interaction 
patterns and discuss treatment options. Methods: Three searches were made in PubMed in January 2016: 1) using the keywords “lithium” [and] “non-steroidal 
anti-inflammatory”; 2) using the keywords “lithium” [and] “diuretics” and the filter “title/abstract”; 3) using the terms “lithium” [and] “toxicity” and the filters 
“title” [and] “review”. From the 293 remaining articles, 10 were selected. Another search in Scielo.org was made, using the term “lítio” and the filter “Psiquiatria”. 
Two articles were selected from the initial 53. Six textbooks were added to expand the evidence, achieving a total of 18 references. Results: The majority of 
NSAIDs and diuretics rises lithium levels, specially thiazides. However, some show great variability or no interaction at all, and others even decrease lithium levels. 
Discussion: Lower-doses, shorter durations, lithium adjustments and levels’ follow-ups are recommended, especially in elderly and multiple co-morbid patients.
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Introduction
Lithium is a mood stabilizer frequently used in bipolar disorder and 
occasionally in severe or recurrent unipolar depression, reducing also 
the risk of suicide. Non-steroidal anti-inflammatory drugs (NSAIDs) 
– for their analgesic, antipyretic and anti-inflammatory effects – and 
diuretics – for their blood pressure and edema reduction effects – are 
frequently prescribed, especially in the elderly, who are particularly 
susceptible to lithium’s toxicity1-11.
The co-administration of this narrowed therapeutic window 
drug with NSAIDs and diuretics is common, but seldom mentioned. 
This issue is even more relevant due to the inexistence of robust 
studies focusing the myriad of possible interactions of lithium with 
the multiplicity of NSAIDs and diuretics that exist nowadays, with 
a significant part of the actual evidence coming from case studies 
and small clinical trials1-5,10,12.
Therefore, this article intends to make a global review of the 
matter, having as main objectives to identify the different types of 
NSAID’s and diuretics’ interactions patterns with lithium and to 
propose treatment alternatives.
Methods
Three initial bibliographical searches were made in PubMed’s 
database, in January 2016. For the first one, the MeSH terms “lithium” 
[and] “non-steroidal anti-inflammatory” were used; for the second 
one were used the terms “lithium” [and] “diuretics” and then the 
filter “title/abstract” was applied to narrow the search; for the third 
one were used the terms “lithium” [and] “toxicity”, and then were 
also applied the filters “title” [and] “review”. Therefore, the searches 
resulted in 146, 123 and 24 articles correspondingly (n = 293), from 
which 10 articles were selected (6, 3 and 1 respectively), accordingly 
with the objectives of this review. 
Afterwards, but also in January 2016, an additional search in 
Scielo.org database was made, using the term “lítio”, resulting in 238 
articles. To narrow the search, the filter “Psiquiatria” was applied and 
from this initial 53 articles’ pool, 2 were selected accordingly with 
the defined objectives.
To expand the scientific evidence found, more sources were 
added through bibliographic review of 6 textbooks based on strong 
international scientific evidence, achieving a total of 18 bibliographic 
references for this critical literature review (Figure 1).
Results and discussion
Lithium’s pharmacokinetics and pharmacodynamics
Lithium is administrated in the form of lithium’s carbonate and its 
elimination is practically all processed by the kidneys (one half in 
≈12h and the other one in 1-2 weeks). This explains why lithium 
blood measurements are done 4-5 days after the beginning of 
treatment and 12h after the last dose. About 80% of the lithium 
filtrate is reabsorbed (≈60% in the proximal tubule and ≈20% in the 
loop of Henle and collector duct)1,2,5,9-11. 
This way, medications that reduce the glomerular filtration 
rate (like NSAIDs and hypertension drugs that interfere with the 
renin-angiotensin-aldosterone system) or that stimulate lithium 
reabsorption (like NSAIDs and most diuretics) can contribute to 
lithium levels above the therapeutic window (0,5-1 mmol/L or 0,4-
1,5 mmol/L, admitting an extreme interval)1,2,5,7-11,13.
Figure 1. Article selection flow chart. *Reasons for exclusion: did not meet 
review objectives; not oriented for clinical practice; abstract/full-text could 
not be obtained; duplicated articles.
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It’s well established that the NSAIDs inhibits prostaglandins’ 
synthesis by cyclogeneses blockage (COX1 and COX2), leading to 
two processes that can explain the rise of plasmatic lithium levels. 
On one hand, prostaglandins fall leads to the reduction of renal 
arteries’ flow by vasoconstriction, resulting in decreased glomerular 
filtrate and consequently decreased renal lithium clearance; on the 
other hand, theories postulate that low levels of prostaglandins 
can promote a direct rise in sodium and lithium, because lithium’s 
renal reabsorption is similar to sodium’s and because of the 
presence of several nephron proteins that promote both cations co-
transportation1,5-9,11,12,14.
The diuretics’ interaction however, differs from class to class. 
The majority promotes a rise in sodium renal excretion, conditioning 
a decreased concentration of it and therefore the activation of a 
compensatory mechanism of increased sodium tubular reabsorption 
and, as explained, also of lithium. Situations linked to hypovolemia 
and hyponatremia can also lead to lithium rises by the same 
mechanism1,4-6,8,10,11,15,16.
Although, diuretics’ effects differ according to the nephron’s site of 
action of each drug class. Thiazides and similar produce and increase 
in sodium and lithium reabsorption in the proximal convoluted 
tubule (where their reabsorption is more relevant). Loop diuretics 
(like furosemide) act mainly in the loop of Henle (where lithium 
reabsorption is marginal). Differently, osmotic diuretics (like mannitol) 
and carbonic anhydrase inhibitors (like acetazolamide) increase 
lithium clearance and consequently diminish lithium levels1,3-6,10.
Adverse effects of lithium
Common secondary effects (that occur in non-toxic therapeutic 
doses) can be distinguished from toxic effects (for lithium levels > 
1,5 mmol/L)1,10,11.
The secondary effects can happen in a short or in a long term. 
At a short term are frequent: nausea, vomits, diarrhea, tremor and 
in some cases, ataxia, sedation and cognitive impairment. The most 
frequent long-term effects are: alopecia, acne, hypothyroidism, 
hyperparathyroidism, weight gain, polyuria, polydipsia (due to 
nephrogenic diabetes insipidus) and chronic renal insufficiency 
(mainly due to interstitial nephritis)1,3,5,9-11.
Several risk factors for intoxication are already identified like: 
old age, drugs (diuretics, NSAIDs), renal insufficiency, renal artery 
stenosis, hyponatremic and hypovolemic conditions (cirrhosis, 
cardiac congestive heart failure, nephrotic syndrome, dehydration 
and low-salt diets) and overdose. Interindividual susceptibility and 
changes in lithium levels can therefore lead to several adverse effects, 
described in Table 11,3,5,10,11,13.
Therefore, is vital to closely check the lithium levels until stable 
values are achieved, for instance weekly. Afterwards, a 6-month check 
is recommended for lithium levels and renal and thyroid functions. 
Metabolic control (weight, cholesterol and glycaemia) as well as the 
cardiac function should also be checked more frequently3,9-11.
Lithium and NSAIDs interaction
The majority of NSAIDs (including COX-2 selective inhibitors) show 
moderate risk for increasing plasmatic lithium concentrations. This 
risk is higher for high doses and long-term treatments. Normally, the 
interaction occurs in the first days of co-administration, despite the 
description of interaction months later in some cases6,8,11,17.
Even admitting a class effect, they are still unknown mechanisms 
of interaction that can be the basis of some exceptions. Acetylsalicylic 
acid and sulindac are two of those examples without strong evidence 
of interaction. In other cases, there is a great interindividual 
variability, as accounts for ibuprofen and naproxen (Table 2). Despite 
the average increase in lithium levels with NSAIDs of 10%-25%, there 
are sporadic cases of 100% raise described1,3-8,12-14,17,18.
Table 1. Toxic lithium effects accordingly with lithium plasmatic levels
> 1,5 mmol/L > 2 mmol/L
 – Nausea and diarrhea
 – Polyuria e thirst
 – Psychomotor agitation
 – Myoclonus and fasciculations
 – Muscular weakness
 – Ataxia
 – Lethargy and sedation
 – Cognitive impairment
 – Acute renal insufficiency
 – ECG T-wave changes
 – Seizures
 – Delirium
 – Coma
 – Death
Table 2. Sorts of interactions between lithium and different NSAIDs
Well-established interaction
(↑lithium)
Celecoxib, diclofenac, flurbiprofen, 
indomethacin, ketorolac, 
ketoprofen, lornoxicam, mefenamic 
acid, meloxicam, niflumic acid, 
phenylbutazone, piroxicam
Variable interaction
(↔ or ↑ or ↑↑ lithium)
Ibuprofen and naproxen
Without proven interaction Acetylsalicylic acid and sulindac
↔ no change; ↑ slight increase; ↑↑ moderate increase.
Alternatives to NSAIDs for analgesic effect are paracetamol 
(acetaminophen) and opioids. For Paracetamol there is no evidence 
of interaction with lithium, but for opioids there is an increased 
risk for serotoninergic syndrome. Therefore, if there is a need for 
a NSAID in such cases, one could rather use: 1) acetylsalicylic 
acid or paracetamol (if analgesic or antipyretic effect is needed 
and there are no contraindications); 2) low-fixed dose or topic 
NSAIDs (theoretically less risky, but without studies corroborating 
that)1,2,5,6,12,14,18.
Every time there’s a strict need to use a NSAIDs, the following 
administration recommendations should be respected:
– To inform the patient of the interaction’s risk11,18;
– To use the minimum effective dose for as less time as possible6;
– To monitor lithium levels every time a NSAID is started or 
suspended (4-5 days later on)6,11,13,14,17;
– It is preferable (if possible) to reduce 20%-25% of lithium 
dose when a new NSAID is introduced3,6,14;
– It should be avoided in high risk patients for lithium intoxi-
cation, especially in the elderly and renal insufficients6,10,11.
Lithium and diuretics interaction
The interaction pattern varies with the class of the diuretic and its 
corresponding pharmacokinetics. Disparity in sodium and lithium 
renal reabsorption’s site can explain why thiazides and analogs have a 
strong interaction pattern and loop diuretics and sparing-potassium 
diuretics don’t (Table 3)1,4-6,11,13,15,16.
The report of interaction cases with thiazides have accumulated 
since the 70’s, particularly with hydrochlorothiazide and 
chlorthalidone. These diuretics promote a 25% increase in lithium 
Table 3. Sorts of interactions between lithium and different diuretics
↑↑↑ [lithium] Thiazides and analogs chlorthalidone, 
hydrochlorothiazide, 
indapamide*
Variable interaction
(↔ or ↑ [lithium])
Loop diuretics furosemide
K+-sparing diuretics amiloride*, 
spironolactone*, 
triamterene*
↓↓ [lithium] Osmotic diuretics mannitol, urea
Carbonic anhydrase 
inhibitors
acetazolamide
*Scarce evidence/class effect assumed. ↔ no change; ↑ slight increase; ↑↑↑ severe increase; 
↓↓ moderate decrease.
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levels (with some cases reporting up to 4-fold rise). This effect is 
commonly present in the first days of co-administration. Despite 
the interaction between lithium and most NSAIDs being so 
unpredictable, with thiazides that interaction is much more likely 
(being held as a high-risk interaction). So, its wise to discourage the 
use of such diuretics in lithium medicated patients1,4-6,11,13,16.
For loop diuretics, the scientific evidence is somewhat 
conflicting. Although furosemide didn’t produce changes in 
lithium levels in some cases, in others seemed to be responsible 
for small plasmatic increases, especially in susceptible individuals. 
Also, furosemide’s interaction can occur a little bit latter than 
with thiazides, but usually in the first month. Despite all that, it is 
considered a safer diuretic than thiazides, being mentioned as a 
therapeutic option for nephrogenic diabetes insipidus secondary to 
chronic treatment with lithium1,4-6,11,13,15.
For potassium-sparing diuretics, the evidence is even more 
scarce, with no interaction in most studies and small increases in 
lithium levels on other studies, apparently being amiloride the safest 
option in the class. Despite not being unanimous, these diuretics can 
configure an alternative to thiazides1,3,4,6.
Osmotic diuretics (like mannitol) and carbonic anhydrase 
inhibitors (like acetazolamide) produce an opposite effect 
comparing to the majority of the other diuretics, decreasing lithium 
concentration (being therefore classically used to treat lithium’s 
intoxication). Globally, these drugs are not recommended in lithium 
treated patients, due to high risk for psychiatric unbalance3,4,6.
However, there are several alternatives to diuretics for anti-
hypertension effect, despite the evidence being based mostly on case-
control and in class effect extrapolation. The angiotensin converting 
enzyme (ACE) inhibitors are not recommended because they lead 
to rises in lithium levels, the same being assumed for angiotensin 
II receptor antagonists. Calcium channel blockers – most cases 
mentioning verapamil – can increase sensibility to lithium toxic effects, 
even though decreases in lithium levels are described paradoxically. 
Despite β-blockers could decrease lithium’s clearance, they seem to be 
safer and are commonly prescribed to treat accessory effects of lithium 
(as the common use of propranolol for tremor)1,3,6,5,9,11,13.
So, in the need of a hypotension effect in a patient already 
medicated with lithium is probably preferable to use a β-blocker (if no 
contraindication exists). If a diuretic effect is needed, one could use a 
loop diuretic (like furosemide) or a potassium-sparing diuretic (like 
amiloride or spironolactone). These can be administrated in a low-
dose basis and following the same administration recommendations 
as for NSAIDs (with a different advised reduction of lithium dose of 
25%-50%). Patients medicated with thiazides should suspend these 
drugs because of the high risk for lithium intoxication3-6,11.
Conclusions
The majority of NSAIDs promote an increase in lithium levels and 
some, like Ibuprofen and Naproxen, show great interindividual 
variability. Acetylsalicylic acid doesn’t show evidence of lithium 
interaction. Diuretics also promote lithium increments, particularly 
thiazides, which can be explained by their main action in the proximal 
convoluted tubule, where lithium absorption is higher. Therefore, 
they should be replaced by loop and K+-sparing diuretics, despite the 
limited evidence for these diuretics. Inversely, osmotic and carbonic 
anhydrase inhibitors lead to a significant decrease of lithium levels. If 
it is impossible to remove some NSAIDs and diuretics, they should be 
used in a lower-dose and shorter duration as possible, with lithium 
dose adjustments and levels’ follow-ups. Elderly and multiple co-
morbid patients are considered high risk patients. 
Despite these recommendations, more studies are needed to 
properly assess the probability and severity of these interactions, 
because an important part of evidence is based on few case studies 
and small clinical trials.
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